To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...

(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a ...

Most recently, the drug pulled around 13.3 billion Japanese yen ($87 million) in the third quarter of Eisai’s 2024 fiscal year, which will end March 31. Leqembi collected sales of 29.6 billion ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...